Immunohistochemistry (IHC): Increase the Success of Biomarker Integration in Clinical Development

“With immunohistochemistry (IHC) technology, biomarkers can be identified in tumor biopsies. IHC provides the possibility to better understand biomarker mechanisms in the tumor’s environment. By implementing a robust biomarker validation process, you can increase the success of biomarker integration in clinical development.”

– Amanda Finan, PhD, Head IHC/Histology R&D and Clinical Validations at Cerba Research

HISTOSELECT: How to Overcome Challenges in Antibody Selection?

HISTOSELECT®: The number one solution for direct screening of large numbers of antibodies by immunohistochemistry (IHC).

10-Day Study Start & Custom Test Kit Build at the Height of a Pandemic

Cerba Research initiated custom kit building & distribution for an infectious disease study, during the COVID-19 pandemic, in 10 days. A typical timeline is 8 weeks.

Trial by Ordeal of Unprecedented Global Pandemic

Our CEO, Mario Papillon, was interviewed by Clinical Trials Insight on how Cerba Research helps clients receive novel treatments faster, and how our key differentiators have helped us in the fight against COVID-19.

Download the article using the button below, or read a copy on the Clinical Trials Insight website: https://secure.viewer.zmags.com/publication/955cc33c#/955cc33c/18

Covid-19 and its Ripple Effect on Clinical Trials

Our team came together to write an article on Covid-19 and its ripple effect on clinical trials for the Journal for Clinical Studies. Sofie Vandevyver, Daniel Tanner and Mario Papillon discussed the challenges Covid-19 revealed in clinical trials, the overwhelming amount of different assays for the detection of Covid-19 and which ones to use in clinical studies, and what the future of clinical trials might look like.

Download the article using the button below, or read a copy on the Journal for Clinical Studies’ website (https://issuu.com/mark123/docs/2020-jcs-3-june-web_compressed/22).

Challenges of Covid-19 Testing: Which Test to Use?

Are you using the right Covid-19 test? In the race to contain the COVID-19 pandemic, efficient detection of SARS-CoV-2 was and still remains the cornerstone. On January 23, the first in-house RT-PCR assay was published, quickly followed by the development of multiple commercial kits.

During the webinar, our Cerba biologists will walk participants through the overview of our available testing, discuss the reliability of tests, the current limits in Covid-19 testing, and which sample is the most efficient in each case.

Lastly, Cerba Research’s partner Fulgent will discuss NGS testing and how much we know about the analysis of the virus and its mutations.

Phase 3 Clinical Trial on the Efficacy and Safety of a New Therapy For Post-Exposure Prophylaxis Of COVID-19 And Other Viral Respiratory Illnesses

Phase 2c Clinical Trial on the Efficacy, Safety and Tolerability of Drug-Sensitive Smear-Positive Pulmonary Tuberculosis (DS TB) Treatment

Phase 3 Clinical Trial on the Safety and Efficacy Of Combination Therapies in Patients with Either Extensively Drug-Resistant Tuberculosis (XDR-TB), Pre-XDR-TB Or Treatment Intolerant Or Non- Responsive Multi-Drug Resistant Tuberculosis (MDR-TB)

Phase 3 Clinical Trial on the Efficacy and Safety of a New Therapy in the Treatment of Uncomplicated Influenza